268739-54-4

Basic information

• Product Name: (4R)-MONASTROL
• Synonyms: (4R)-MONASTROL;(R)-Monastrol;(4R)-1,2,3,4-Tetrahydro-4-(3-hydroxyphenyl)-6-methyl-2-thioxo-5-pyrimidinecarboxylic acid ethyl ester
• CAS NO: 268739-54-4
• Molecular Formula: C14H16N2O3S
• Molecular Weight: 292.35
• Mol File: 268739-54-4.mol
• Article Data: 95

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4R)-MONASTROL(CAS DataBase Reference)
• NIST Chemistry Reference: (4R)-MONASTROL(268739-54-4)
• EPA Substance Registry System: (4R)-MONASTROL(268739-54-4)

Safety Data

• Hazardous Substances Data: 268739-54-4(Hazardous Substances Data)

Usage

General Description

(4R)-MONASTROL is a cell-permeable small molecule inhibitor that specifically targets the kinesin Eg5, an essential motor protein involved in the formation and maintenance of the mitotic spindle during cell division. By disrupting the function of Eg5, (4R)-MONASTROL prevents the proper assembly and alignment of chromosomes, leading to mitotic arrest and ultimately cell death. (4R)-MONASTROL has been widely used in research to study the mechanisms of cell division and has shown potential as a therapeutic agent for the treatment of cancer, as targeting Eg5 can disrupt the uncontrolled growth and proliferation of cancer cells. Additionally, (4R)-MONASTROL has been explored for its potential in treating other conditions such as neurological disorders and viral infections, making it a versatile and promising compound for further investigation.

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 141-97-9 ethyl acetoacetate 
• 100-83-4 meta-hydroxybenzaldehyde 
• 1243989-69-6 C₁₈H₂₂N₂O₄S 
• 1243989-70-9 C₁₈H₂₂N₂O₄S 
• 482655-63-0 ethyl 4-(3-((tert-butyldimethylsilyl)oxy)phenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
• 329689-23-8 monastrol 
• 96013-95-5 3-(tert-butyl-dimethyl-sylanyloxy)benzaldehyde 
• 17356-08-0 thiourea 
• 482655-65-2 (S)-3-((2R,3R,4R,5R)-3,4-Bis-benzoyloxy-5-benzoyloxymethyl-tetrahydro-furan-2-carbonyl)-4-[3-(tert-butyl-dimethyl-silanyloxy)-phenyl]-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester 
• 482655-64-1 (R)-3-((2R,3R,4R,5R)-3,4-Bis-benzoyloxy-5-benzoyloxymethyl-tetrahydro-furan-2-carbonyl)-4-[3-(tert-butyl-dimethyl-silanyloxy)-phenyl]-6-methyl-2-thioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid ethyl ester 
• 37622-16-5 thiouronium hydrogensulfate 

Downstream Products

• 1228007-59-7 C₁₉H₂₂N₂O₆S 

Relevant articles and documents

Application of design of experiments (Doe) approach for the optimization of phase-transfer catalyzed biginelli dihydropyrimidinone (dhpm) synthesis

The conventional Biginelli synthesis is more cumbersome and produces lower yields. Several improved methods are reported in the literature to replace the Biginelli catalyst. The design of biocompatible organic transformation is a major concern and a versa

A novel H2S releasing-monastrol hybrid (MADTOH) inhibits L-type calcium channels

A new alleged monastrol-H2S releasing hybrid, named MADTOH, was designed based on the structure of monastrol (M) and 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione (ADTOH) and synthesized in 7.8% overall yield. MADTOH was shown to be an H2S donor under physiological conditions. In addition, the hybrid causes a decrease in global calcium transient in cardiomyocytes similar to nifedipine (NIFE), taken as a positive control. Whole-cell voltage-clamp showed that MADTOH decreases L-type Ca2+ current in isolated ventricular cardiomyocytes.

Concentrated solar radiation as a renewable heat source for a preparative-scale and solvent-free Biginelli reaction

A well-known Biginelli reaction for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones/thiones was performed in an environmentally responsible manner. Large numbers of substrates were screened, and found to give excellent yields of the desired products. In